Merck gains FDA priority review for sotatercept BLA
An investigational activin signalling inhibitor, sotatercept is intended for usage in adult PAH patients. A regulatory decision on the approval of the therapy is anticipated on 26 March
BridgeBio Pharma has entered into a strategic partnership with National Resilience (Resilience) for the manufacturing and advancement of two investigational gene therapies, BBP-812 and BBP-631.
ALTUVIIIO, also known as efanesoctocog alfa, is an antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein used for perioperative management of bleeding, controlling bleeding episodes, and routine prophylaxis. The recommended